Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. Depemokimab helped ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

The GSK (LSE: GSK) share price is a nightmare and there’s little sign of respite for long-suffering investors. Shares in the FTSE 100 pharmaceutical giant now trade 10.18% lower than five years ago.